Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Cesare Gridelli

Showing results (41-50 of 357) with videos related to

Pageof 36
Sort By:
Translational Lung Cancer Research|February 2, 2019
Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?Francesca Casaluce, Cesare Gridelli
Annals of Translational Medicine|February 5, 2020
Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?Cesare Gridelli, Assunta Sgambato
Annals of Translational Medicine|November 26, 2020
The adjuvant regimen for resected EGFR mutated patients: the "same-for-all-therapy" or not?Cesare Gridelli, Francesca Casaluce
Expert Review of Respiratory Medicine|May 23, 2019
Combining immunotherapies to treat non-small cell lung cancerAlessia Spagnuolo, Cesare Gridelli
Journal of Thoracic Disease|July 27, 2012
EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European populationCesare Gridelli, Antonio Rossi
Expert Opinion on Pharmacotherapy|February 12, 2025
Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancerAlessia Spagnuolo, Cesare Gridelli
Expert Opinion on Pharmacotherapy|January 8, 2010
The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trialCesare Gridelli, Massimo Di Maio
Current Medicinal Chemistry|April 23, 2002
Vinorelbine in the treatment of non-small cell lung cancerCesare Gridelli, Rocco De Vivo
European Journal of Cancer (Oxford, England : 1990)|April 2, 2013
The PARAMOUNT study and the re-challenge chemotherapy issue in advanced non-small cell lung cancerCesare Gridelli, Luis Paz-Ares
Expert Opinion on Emerging Drugs|August 25, 2017
An update on the developing mitotic inhibitors for the treatment of non-small cell carcinomaPaola Claudia Sacco, Cesare Gridelli
Pageof 36

Showing results (41-50 of 357) with videos related to

Sort By:
Pageof 36
Translational Lung Cancer Research|February 2, 2019
Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?Francesca Casaluce, Cesare Gridelli
Annals of Translational Medicine|February 5, 2020
Elderly patients and PD-L1-positive advanced non-small cell lung cancer: is pembrolizumab monotherapy effective and safe?Cesare Gridelli, Assunta Sgambato
Annals of Translational Medicine|November 26, 2020
The adjuvant regimen for resected EGFR mutated patients: the "same-for-all-therapy" or not?Cesare Gridelli, Francesca Casaluce
Expert Review of Respiratory Medicine|May 23, 2019
Combining immunotherapies to treat non-small cell lung cancerAlessia Spagnuolo, Cesare Gridelli
Journal of Thoracic Disease|July 27, 2012
EURTAC first-line phase III randomized study in advanced non-small cell lung cancer: Erlotinib works also in European populationCesare Gridelli, Antonio Rossi
Expert Opinion on Pharmacotherapy|February 12, 2025
Investigating osimertinib plus chemotherapy in EGFR-mutated advanced non-small cell lung cancerAlessia Spagnuolo, Cesare Gridelli
Expert Opinion on Pharmacotherapy|January 8, 2010
The role of pemetrexed as maintenance treatment in advanced NSCLC: a Phase III randomized trialCesare Gridelli, Massimo Di Maio
Current Medicinal Chemistry|April 23, 2002
Vinorelbine in the treatment of non-small cell lung cancerCesare Gridelli, Rocco De Vivo
European Journal of Cancer (Oxford, England : 1990)|April 2, 2013
The PARAMOUNT study and the re-challenge chemotherapy issue in advanced non-small cell lung cancerCesare Gridelli, Luis Paz-Ares
Expert Opinion on Emerging Drugs|August 25, 2017
An update on the developing mitotic inhibitors for the treatment of non-small cell carcinomaPaola Claudia Sacco, Cesare Gridelli
Pageof 36